<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195763</url>
  </required_header>
  <id_info>
    <org_study_id>ALX-HPP-503</org_study_id>
    <nct_id>NCT04195763</nct_id>
  </id_info>
  <brief_title>Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)</brief_title>
  <official_title>A Prospective Study to Evaluate the Patient Reported Quality of Life Prior to and After Strensiq® Treatment in Adults With Pediatric Onset Hypophosphatasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xcenda, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study will evaluate the treatment effect of Strensiq (asfotase alfa) on
      Patient Reported Outcomes (PROs) in participants diagnosed with pediatric-onset
      hypophosphatasia (HPP) registered in the patient support program managed by OneSource™.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants consenting to participate in this study will be asked to complete study
      questionnaires by phone interviews upon consenting (Baseline), and up to 12 months following
      treatment initiation with asfotase alfa. Demographic and clinical characteristics of
      participants in the study will be characterized.

      This is an observational study and no intervention will be administered. Participants will be
      treated in accordance with standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 6, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline In Patient Reported Outcomes (PROs) Questionnaire Scores</measure>
    <time_frame>Baseline, up to 12 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypophosphatasia</condition>
  <arm_group>
    <arm_group_label>Participants with Pediatric-onset HPP</arm_group_label>
    <description>Adult participants diagnosed with pediatric-onset HPP, newly prescribed treatment with asfotase alfa, and registered in the patient support program managed by OneSource.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>asfotase alfa</intervention_name>
    <description>This is an observational study and no intervention will be administered. All participants will be treated by their physician in accordance with standard of care. All medications are commercially available and will be used as directed by the treating physician.</description>
    <arm_group_label>Participants with Pediatric-onset HPP</arm_group_label>
    <other_name>Strensiq®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female participants ≥18 years of age who have been diagnosed with pediatric-onset
        HPP, have been newly prescribed treatment with asfotase alfa, and are registered in the
        patient support program managed by OneSource will be invited to participate.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years old

          -  Clinical diagnosis of pediatric-onset HPP

          -  Naïve to asfotase alfa

          -  Expected to begin treatment with asfotase alfa for HPP

          -  Registered in OneSource

          -  Willing and able to provide voluntary, verbal informed consent to participate in this
             study

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Unable to speak and understand English

          -  Unable or unwilling to complete the study surveys via telephone interview at the
             protocol-required time points
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xcenda, LLC</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34685</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric-onset hypophosphatasia</keyword>
  <keyword>Pediatric-onset</keyword>
  <keyword>Hypophosphatasia</keyword>
  <keyword>HPP</keyword>
  <keyword>Patient reported outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypophosphatasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

